# TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

> **NCT06676449** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 432 (estimated)

## Conditions studied

- Esophageal Carcinoma
- Radiotherapy
- Immunotherapy

## Interventions

- **DRUG:** Immunotherapy
- **DRUG:** chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens
- **RADIATION:** TDLN-sparing RT

## Key facts

- **NCT ID:** NCT06676449
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2028-10-31
- **Final completion:** 2030-10-30
- **Target enrollment:** 432 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06676449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06676449, "TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06676449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*